1. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?

   • Tamer Othman
   • Alex Herrera
   • Matthew Mei

   T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) 06 January 2021 Pages: 1 - 7

2. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents

   • Edward Nabrinsky
   • Alexey V. Danilov
   • Paul B. Koller

   T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) 28 January 2021 Pages: 8 - 18

3. A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine

   • Narendranath Epperla
   • Mehdi Hamadani

   T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) 25 January 2021 Pages: 19 - 24

4. Targeted Therapies for Follicular Lymphoma

   • Jennifer Girard
   • Yasmin Karimi
   • Tycel Phillips

   T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) 22 March 2021 Pages: 25 - 31

5. Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies

   • Taha Al-Juhaishi
   • Sairah Ahmed

   T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) 25 February 2021 Pages: 32 - 39

6. Lessons Learned Treating Patients with Multiple Myeloma in Resource-Constrained Settings

   • Guillermo J. Ruiz-Argüelles
   • David Gómez-Almaguer

   Multiple Myeloma (P Kapoor, Section Editor) 11 March 2021 Pages: 40 - 44

7. When to Use Targeted Therapy for the Treatment of Follicular Lymphoma

   • Loretta J. Nastoupil

   B Cell NHL, T Cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 02 April 2021 Pages: 45 - 51

8. Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra

   • Francesca Montanari
   • Manuela Orjuela-Grimm

   B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 05 February 2021 Pages: 52 - 60

9. AYA Considerations for Aggressive Lymphomas

   • Gabriela Llaurador
   • Lisa Giulino-Roth

   B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 16 March 2021 Pages: 61 - 71

10. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma

    • Anupama Doraiswamy
    • Mansi R. Shah
    • Rajat Bannerji

    B Cell NHL, T Cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 22 February 2021 Pages: 72 - 81

    

11. Invited Review: Will Consolidation with ASCT Be a Thing of the Past for MCL and PTCL?

    • Alessandro Broccoli
    • Lisa Argnani
    • Pier Luigi Zinzani

    Topical Collection on B Cell NHL, T Cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 01 March 2021 Pages: 82 - 88

    

12. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia

    • Sangeetha Venugopal
    • Naval Daver
    • Farhad Ravandi

    Acute Myeloid Leukemias (U Borate, Section Editor) 25 February 2021 Pages: 89 - 96

13. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options

    • Daniel R. Richardson
    • Steven D. Green
    • Joshua F. Zeidner

    Acute Myeloid Leukemias (U Borate, Section Editor) 20 February 2021 Pages: 97 - 111

14. High-Dimensional Immune Monitoring for Chimeric Antigen Receptor T Cell Therapies

    • Sujata Sharma
    • David Quinn
    • Iulian Pruteanu-Malinici

    CART and Immunotherapy (M Ruella and P Hanley, Section Editors) 15 January 2021 Pages: 112 - 116